💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

U.S. stocks open higher on upbeat retail sales; Dow Jones up 0.25%

Published 01/14/2014, 09:41 AM
U.S. stocks rise after retail sales data
NDX
-
UK100
-
FCHI
-
DJI
-
DE40
-
STOXX50
-
JP225
-
HK50
-
WFC
-
IXIC
-

Investing.com - U.S. stocks opened higher on Tuesday, supported by the release of upbeat U.S. retail sales data, after comments by Atlanta Federal Reserve President Dennis Lockhart sent U.S. equities broadly lower on Monday.

During early U.S. trade, the Dow Jones Industrial Average added 0.25%, the S&P 500 index rose 0.30%, while the Nasdaq Composite index advanced 0.48%.

The U.S. Commerce Department said that retail sales rose by a seasonally adjusted 0.2% last month, beating expectations for a 0.1% increase. Retail sales for November were revised down to a 0.4% gain from a previously reported increase of 0.7%.

Core retail sales, which exclude automobile sales, edged up 0.7% last month, above forecasts for a 0.4% increase. Core sales rose by 0.1% in November.

U.S. equities were hit on Monday after Atlanta Fed President Dennis Lockhart said that the U.S. central bank should push ahead with its efforts to wind down monetary stimulus.

Financial stocks were in focus, as Wells Fargo reported better-than-expected fourth quarter earnings but said revenue figures trailed forecasts, sending shares down 1.01%.

JPMorgan Chase rallied 1.30% after reporting better-than-expected fourth-quarter earnings and revenue. The lender was recently in the spotlight after having to pay penalties for not reporting suspicions of fraud by Bernie Madoff.

Among tech stocks, Juniper Networks rose 0.39%, after Bloomberg reported that the maker of computer-networking equipment was being targeted by activist hedge fund Elliott Management.

Separately, Google gained 0.68% after saying it would purchase digital-thermostat manufacturer Nest Labs for USD3.2 billion.

In the pharmaceutical sector, Merck & Co. tumbled 1% even though a preliminary review posted on the U.S. Food and Drug Administration's web site on Monday cited "robustly positive" clinical trial results for the U.S. drugmaker and said its blood clot-preventing drug vorapaxar should be approved.

Across the Atlantic, European stock markets were lower. The EURO STOXX 50 slipped 0.16%, France’s CAC 40 edged down 0.19%, Germany's DAX fell 0.27%, while Britain's FTSE 100 dipped 0.01%.

During the Asian trading session, Hong Kong's Hang Seng Index dropped 0.43%, while Japan’s Nikkei 225 Index plunged 3.08%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.